- CFO Spotlights
- Profiles
- Naresh Tanna
Profile
Naresh Tanna
Chief Financial Officer, Precision BioSciences, Inc.
In the seat. First published here October 28, 2026; built from records as of October 28, 2026.
Naresh Tanna has been Chief Financial Officer of Precision BioSciences, Inc. since August 1, 2026, according to the company's filing of July 27, 2026.1
The filing gives Naresh Tanna's previous role as Vice President of Investor Relations and Chief of Staff to the Chief Executive Officer at Precision BioSciences, Inc.1 Naresh Tanna already worked at Precision BioSciences, Inc. when appointed, so the record counts the move as an internal promotion.1
Seats
The seat in the record
| Company | Title as filed | Standing |
|---|---|---|
| Precision BioSciences, Inc. (DTIL) Biological Products, (No Diagnostic Substances) | Chief Financial Officer | In the seat |
Company names link to the company's page in the record at CFO Tribune, which holds the seat history.
The record
Filing by filing, latest first
- August 1, 2026effective
Precision BioSciences, Inc. appointed Naresh Tanna as Chief Financial Officer, effective August 1, 2026. Profile of Alex Kelly.
Kelly’s promotion to Chief Operating Officer, the Board appointed Naresh Tanna, age 45, as Chief Financial Officer of the Company.
[1] Filing by Precision BioSciences, Inc., filed with the SEC on July 27, 2026. Read the filing. The record at CFO Tribune.
Sources
Sources
- Current report filed with the SEC, Precision BioSciences, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed July 27, 2026. sec.gov; record.
Corrections and removal
If a line here is wrong, or Naresh Tanna wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.